OC
COYA icon

Oppenheimer & Co’s Coya Therapeutics COYA Stock Holding History

Oppenheimer & Co’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Hold
18,000
– – ﹤0.01% 1719
2026
Q1 		$70.9K Buy
18,000
+4,000
+29% +$18.7K ﹤0.01% 1655
2025
Q4 		$81.2K Buy
+14,000
New +$85.1K ﹤0.01% 1501

Other funds holding COYA

DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Oppenheimer & Co's COYA Position: Q2 2026 in Review

Oppenheimer & Co held its Coya Therapeutics (COYA) position steady in Q2 2026 at 18,000 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Oppenheimer & Co first reported a position in COYA in Q4 2025 and has held it in 3 quarters since. 54 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • Oppenheimer & Co held 18,000 shares of Coya Therapeutics worth $105K as of Q2 2026.
  • Oppenheimer & Co left its Coya Therapeutics share count unchanged in Q2 2026.
  • Coya Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1719 holding.
  • Oppenheimer & Co first reported a position in Coya Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 54 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.